Star Therapeutics: Valuation, Funding & Investors
Star Therapeutics is a clinical-stage biotechnology company focused on discovering and developing novel antibodies for the treatment of bleeding disorders and other diseases. Its lead program, VGA039, is an innovative antibody targeting Protein S to restore blood clotting balance, currently undergoing a pivotal Phase 3 trial for von Willebrand Disease.
Leadership & Board
- Current Number of Employees
- 45
- Current LinkedIn Followers
- 5,660
Latest Estimated Valuation
- Total Amount Raised
- $125M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $125M
- Latest Funding Round
- Series D
Employee Trend
Star Therapeutics had 45 employees as of November 9, 2026. The number of employees increased by 0 (0.00%) week-over-week.
45Latest Employee Count
0(0.00%)Week-Over-Week Change
Social Trend
Star Therapeutics had 5,660 followers as of November 9, 2026. The number of followers increased by 73 (1.31%) week-over-week.
5,660Latest Followers Count
73(1.31%)Week-Over-Week Change
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Oct 08, 2025 | Series D | $125.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Janus Henderson Investors | Series D |
| Viking Global Investors | Series D |
| Frazier Life Sciences | Series D |
| Sanofi Ventures | Series D |
| GordonMD Global Investments | Series D |
Similar Companies
A snapshot of private companies similar to Star Therapeutics, helping you discover and navigate related company profiles.
Related News and Analysis
